



RECEIVED  
OCT 17 2001

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02, U.S. Patent & Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/657,276	
	Filing Date	September 7, 2000	
	First Named Inventor	BRIDON et al.	
	Group Art Unit	1619	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	9	Attorney Docket No.	500862002300

**ENCLOSURES (check all that apply)**

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form   | <input type="checkbox"/> Assignment Papers<br>(for an Application)                         | <input type="checkbox"/> After Allowance Communication to Group                               |
| <input type="checkbox"/> Fee Authorized to Charge<br>Deposit Account                      | <input type="checkbox"/> Drawing(s)  | <input type="checkbox"/> Appeal Communication to Board of<br>Appeals and Interferences        |
| <input type="checkbox"/> Amendment / Reply  | <input type="checkbox"/> Licensing-related Papers  | <input type="checkbox"/> Appeal Communication to Group<br>(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final  | <input type="checkbox"/> Petition  | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declarations  | <input type="checkbox"/> Petition to Convert to a<br>Provisional Application               | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request  | <input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s): <b>Postcard.</b>                      |
| <input type="checkbox"/> Express Abandonment Request                                      | <input type="checkbox"/> Terminal Disclaimer   |   |
| <input type="checkbox"/> Second Supplemental Information<br>Disclosure Statement - 3 pgs  | <input type="checkbox"/> Request for Refund  |   |
| <input checked="" type="checkbox"/> Form PTO-1449 - 1 pg (with 2<br>Reference CITED only) | <input type="checkbox"/> CD, Number of CD(s) _____   |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                           | Remarks  |   |
| <input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application             |  |   |
| <input type="checkbox"/> Response to Missing Parts<br>under 37 CFR 1.52 or 1.53           |  |   |

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual Name	Morrison & Foerster LLP 425 Market Street San Francisco, California 94105-2482 Michael R. Ward, Reg. No. 38,651
Signature	<i>Michael R. Ward</i>
Date	September 28, 2001

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 28, 2001.

*LILIA OLSEN*

sf-1177065



RECEIVED

OCT 17 2001

PATENT

Docket No. 500862002300  
TECH CENTER 1800/2000

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on September 28, 2001.

Lilia Olsen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

D. P. BRIDON et al.

Serial No.: 09/657,276

Filing Date: September 7, 2000

For: PROTECTION OF ENDOGENOUS  
THERAPEUTIC PEPTIDES FROM  
PEPTIDASE ACTIVITY THROUGH  
CONJUGATION TO BLOOD  
COMPONENTS

Examiner: To Be Assigned

Group Art Unit: 1619

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Both U.S. patent applications cited correspond with PCT applications that were previously submitted; the specification for U.S. patent application 09/424,571 corresponds to WO 99/48536, and the specification for U.S. patent application 09/530,891 corresponds to WO 99/24462. As such, copies of these applications are not supplied with this information disclosure statement.

This Information Disclosure Statement is submitted:

- ☒ **Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.**
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of \* is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 500862002300. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 28, 2001

Respectfully submitted,

By: Michael R. Ward  
Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522